Fujifilm
Search results
FUJIFILM Diosynth Biotechnologies is a CDMO partner for life. Our focus is to combine technical leadership in cell culture, microbial fermentation, and cell and gene therapy with world class cGMP manufacturing facilities to advance tomorrow’s medicines.
Fujifilm Careers: Learn about working at FUJIFILM Diosynth Biotechnologies – a CDMO that partners with global biopharma and biotech companies. Explore careers with us.
FUJIFILM Diosynth Biotechnologies works in strategic collaboration with biopharmaceutical and biotech companies to develop and manufacture the latest in biologics, advanced therapies and vaccines.
For over 30 years, FUJIFILM Diosynth Biotechnology’s mission has been advancing tomorrow’s medicine. As a CDMO, we work in partnership with the most innovative biopharma and biotech companies...
Oct 14, 2021 · The new facility will offer large-scale cell culture manufacturing of bulk drug substance production with 8 x 20,000L bioreactors with the potential to expand and add a further 24 x 20,000L bioreactors based on market demand.
Aug 24, 2023 · FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization partner for the development and manufacture of biologics, vaccines, cell and gene therapies, and oncolytic viruses.
FUJIFILM Diosynth Biotechnologies, abbreviated FDB and also referred to simply as Diosynth, is a biopharmaceutical contract manufacturing organization that develops manufacturing processes and manufactures active ingredients and provides fill and finish services for pharmaceutical companies.
Jun 1, 2023 · FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization partner for the development and manufacture of biologics, vaccines and advanced therapies.
Mar 18, 2021 · The new facility will offer large-scale cell culture manufacturing of bulk drug substance production with 8 x 20,000L bioreactors with the potential to expand and add a further 24 x 20,000L bioreactors based on market demand.
The new space is designed to maximize the emerging SymphonX™ [1] technology for clinical and commercial manufacturing. Once the expansion is complete in late 2023/early 2024, the manufacturing capacity of the large-scale microbial production facility will increase by 70%.
